{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:42:46Z","timestamp":1790692966725,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009527","name":"Statens Serum Institut","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009527","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007137","name":"Helse Nord RHF","doi-asserted-by":"publisher","award":["SFP1051-12"],"award-info":[{"award-number":["SFP1051-12"]}],"id":[{"id":"10.13039\/501100007137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007137","name":"Helse Nord RHF","doi-asserted-by":"publisher","award":["2014-15-0201-00204"],"award-info":[{"award-number":["2014-15-0201-00204"]}],"id":[{"id":"10.13039\/501100007137","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ijantimicag.2019.11.008","type":"journal-article","created":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T11:15:56Z","timestamp":1574507756000},"page":"105851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model"],"prefix":"10.1016","volume":"55","author":[{"given":"Ilya Nikolaevich","family":"Zykov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Frimodt-M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Sm\u00e5brekke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnfinn","family":"Sundsfjord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8rjan","family":"Samuelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0001","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1517\/14656566.2016.1154538","article-title":"Treatment options for extended-spectrum \u03b2-lactamase (ESBL) and AmpC-producing bacteria","volume":"17","author":"D'Angelo","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0002","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jhin.2015.01.008","article-title":"Multidrug-resistant Gram-negative bacteria: a product of globalization","volume":"89","author":"Hawkey","year":"2015","journal-title":"J Hosp Infect"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2019.11.008_bib0003","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/infdis\/jiw282","article-title":"The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace","volume":"215","author":"Logan","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0004","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0005","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1469-0691.2004.00737.x","article-title":"Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole","volume":"10","author":"Kerrn","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0006","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/jac\/dkt368","article-title":"Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria","volume":"69","author":"Dewar","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0007","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2147\/IDR.S163280","article-title":"Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review","volume":"11","author":"Jans\u00e5ker","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0008","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cmi.2015.05.022","article-title":"Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin","volume":"21","author":"Giske","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0009","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jac\/dki239","article-title":"CTX-M: changing the face of ESBLs in the UK","volume":"56","author":"Livermore","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijantimicag.2009.04.012","article-title":"The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections","volume":"34","author":"Schito","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0011","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10096-011-1183-4","article-title":"In vitro activity of \u03b2-lactam antibiotics against CTX-M-producing Escherichia coli","volume":"30","author":"T\u00e4rnberg","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/23744235.2015.1087648","article-title":"The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010\u20132011","volume":"48","author":"Zykov","year":"2016","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0013","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/jac\/dki451","article-title":"Activity of mecillinam against ESBL producers in vitro","volume":"57","author":"Thomas","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0014","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1093\/jac\/dks215","article-title":"Mecillinam\/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"67","author":"Lampri","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0015","doi-asserted-by":"crossref","first-page":"O267","DOI":"10.1111\/1469-0691.12374","article-title":"Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli","volume":"20","author":"Hickman","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/46.suppl_1.9","article-title":"Comparative potency of mecillinam and other \u03b2-lactam antibiotics against Escherichia coli strains producing different \u03b2-lactamases","volume":"46","author":"Sougakoff","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0017","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1600-0463.2011.02766.x","article-title":"Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae","volume":"119","author":"Titelman","year":"2011","journal-title":"APMIS"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0018","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/jac\/dkr299","article-title":"Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media","volume":"66","author":"Perry","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0019","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1093\/jac\/dku204","article-title":"In vitro activity of mecillinam against Enterobacteriaceae with NDM-1 carbapenemase","volume":"69","author":"Marrs","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187832","article-title":"Molecular and epidemiological characterization of carbapenemase-producing Enterobacteriaceae in Norway, 2007 to 2014","volume":"12","author":"Samuelsen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0021","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ebiom.2017.08.021","article-title":"Reversion of high-level mecillinam resistance to susceptibility in Escherichia coli during growth in urine","volume":"23","author":"Thulin","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0022","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1128\/AAC.04819-14","article-title":"Amdinocillin (mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli","volume":"59","author":"Thulin","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0023","unstructured":"B\u00e6rheim A, Grude N. Antibiotikabruk i prim\u00e6rhelsetjenesten, cystitt [Antibiotic use in primary health care, cystitis]. 2019. http:\/\/www.antibiotikaiallmennpraksis.no\/index.php?action=showtopic&topic=vXmA4Spa[accessed 12 July 2019]."},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0024","unstructured":"Johansen IS, Gerstoft J, Engberg JH, Frimodt-M\u00f8ller N, B\u00f6cher S, Ntgaard U, et al. Vejledning i bruk af antibiotika. Urogenitalsystemet [Guidance on the use of antibiotics. Urogenital system]. 2018. https:\/\/pro.medicin.dk\/Specielleemner\/Emner\/318028[accessed 12 July 2019]."},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0025","unstructured":"L\u00e4kemedelsverket. UVI\u2013Urinv\u00e4gsinfektioner i \u00f6ppenv\u00e5rd, behandlingsrekommendation [Urinary tract infections in outpatient care, treatment recommendation]. https:\/\/lakemedelsverket.se\/uvi[accessed 12 July 2019]."},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0026","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jac\/dkt404","article-title":"Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections","volume":"69","author":"Jans\u00e5ker","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0027","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/mdr.2011.0161","article-title":"Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"18","author":"Titelman","year":"2012","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0028","doi-asserted-by":"crossref","first-page":"e85889","DOI":"10.1371\/journal.pone.0085889","article-title":"High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli","volume":"9","author":"S\u00f8raas","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0029","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/jac\/dky230","article-title":"Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study","volume":"73","author":"Bollestad","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0030","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/AAC.47.3.1002-1009.2003","article-title":"Effects of sulfamethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection mouse model","volume":"47","author":"Kerrn","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02560-17","article-title":"Pharmacokinetics and pharmacodynamics of fosfomycin and its activity against extended-spectrum \u03b2-lactamase-, plasmid-mediated AmpC-, and carbapenemase-producing Escherichia coli in a murine urinary tract infection model","volume":"62","author":"Zykov","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157718","article-title":"A bacterial analysis platform: an integrated system for analysing bacterial whole genome sequencing data for clinical diagnostics and surveillance","volume":"11","author":"Thomsen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0033","series-title":"49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12\u201315 September 2009","article-title":"In vivo PK\/PD of mecillinam in a murine urinary tract infection (UTI) model","author":"Vingsbo Lundberg","year":"2009"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0034","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","article-title":"What's wrong with Bonferroni adjustments","volume":"316","author":"Perneger","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0035","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1128\/AAC.18.6.952","article-title":"Pharmacokinetics of mecillinam in health subjects","volume":"18","author":"Gambertoglio","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0036","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/AAC.44.1.156-163.2000","article-title":"Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies","volume":"44","author":"Hvidberg","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0037","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1093\/jac\/dks224","article-title":"Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model","volume":"67","author":"Jakobsen","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0038","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jac\/dki002","article-title":"Intracellular persistence of Escherichia coli in urinary bladders from mecillinam-treated mice","volume":"55","author":"Kerrn","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0039","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1371\/journal.pmed.0040329","article-title":"Detection of intracellular bacterial communities in human urinary tract infection","volume":"4","author":"Rosen","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0040","doi-asserted-by":"crossref","first-page":"e00055","DOI":"10.1128\/mSphere.00055-15","article-title":"Uropathogenic Escherichia coli metabolite-dependent quiescence and persistence may explain antibiotic tolerance during urinary tract infection","volume":"1","author":"Leatham-Jensen","year":"2016","journal-title":"mSphere"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0041","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/jac\/dkx087","article-title":"A combination of mecillinam and amoxicillin\/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam","volume":"72","author":"Birgy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.008_bib0042","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apm.12147","article-title":"Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women","volume":"122","author":"Monsen","year":"2014","journal-title":"APMIS"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791930322X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791930322X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:27:53Z","timestamp":1778549273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485791930322X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S092485791930322X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.11.008","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105851"}}